Sjogren’s fails a clinical trial with rituximab and a cost analysis. Even with a significant discount, it’s still not cost effective.
The first-ever treatment guidelines for systemic Sjogren’s syndrome have been issued highlighting the need to alleviate symptoms, improve quality of life and prevent further damage.
The American College of Rheumatology and the European League Against Rheumatism have published an international set of classification criteria for primary Sjögren's syndrome.
The Rheumatology Journal Club resumes its Twitter chat series this week with a focus on rheumatological immune-related adverse events in immunotherapy.
Clinicians should pay more attention to neurological signs in patients with high-activity primary Sjogren’s Syndrome or those with prior neurological involvements.
Autoantibodies against carbamylated proteins in Sjögren’s syndrome could be used as a new biomarker.
B-cells that are active in lupus may also play a role in Sjögren’s syndrome. A new study finds that the same B-cell depleter drug, belimumab (Benlysta) approved for lupus, may also benefit Sjögren’s patients.
Three eminent rheumatologists have posted their comprehensive textbook of rheumatology online, open-access and free. They are calling it Rheumaknowledgy.
The increased risk for venous thromoboembolism after surgery among patients with rheumatic disease appears to trace to those conditions with a clotting component. However, joint surgery in general has a high risk of this complication.
A Miami rheumatologist tells why he has donated $1 million to offer his colleagues in community practice the chance to pursue their own clinical theories.